Trial reportEuropean journal of nuclear medicine and molecular imaging2018
Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy.
Trial report in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07628075 (Long-Axial Field of View), which is not on this map. Cited by 106 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Long-Axial Field of View (LAFOV) [18F]FDG PET/CT Imaging in Large Vessel Vasculitis (LVV): Protocol Optimisation Study.
Who cites it
106 citing papers in PubMed, 6 syntheses or guidelines pooled it, 229 citations in OpenAlex.
- EANM/SNMMI guideline/procedure standard for [European journal of nuclear medicine and molecular imaging · 2025Guideline
- Pooled it
- ACR Appropriateness Criteria® Noncerebral Vasculitis.Journal of the American College of Radiology : JACR · 2021Guideline
- Diagnostic value of [18F]FDG-PET/CT for treatment monitoring in large vessel vasculitis: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2021Pooled it
- 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.Arthritis care & research · 2021Guideline
- 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.Arthritis & rheumatology (Hoboken, N.J.) · 2021Guideline
- The Clinical Impact of UsingContrast media & molecular imaging · 2019Trial
- Digital [European journal of nuclear medicine and molecular imaging · 2026Article
- Visual analysis of [European journal of nuclear medicine and molecular imaging · 2026Article
- Aortitis-Associated Left Main Obstruction Requiring Urgent CABG: When Youth Is Not Low Risk.JACC. Case reports · 2026Article
- The real-world experience of combined cranial and large vesselClinical rheumatology · 2026Article
- The Role of FDG-PET in the Diagnosis and Monitoring of Large-Vessel Vasculitis.Current rheumatology reports · 2025Review
- The Role of Imaging in Monitoring Large Vessel Vasculitis: A Comprehensive Review.Biomolecules · 2025Review
- Positron Emission Tomography in Takayasu Arteritis: A Review Including Patterns of Vascular Involvement Across Modalities and Regions.Journal of clinical medicine · 2025Review
- Emerging PET radiotracers for vascular imaging.Rheumatology (Oxford, England) · 2025Review
- Comparison of [EJNMMI reports · 2025Article
- A Machine Learning Model Based on Radiomic Features as a Tool to Identify Active Giant Cell Arteritis on [Diagnostics (Basel, Switzerland) · 2025Article
- Comparison of [European journal of nuclear medicine and molecular imaging · 2025Article
- Hybrid cardiovascular imaging. A clinical consensus statement of the european association of nuclear medicine (EANM) and the european association of cardiovascular imaging (EACVI) of the ESC.European journal of nuclear medicine and molecular imaging · 2025Review
- Can FDG PET Serve as a Clinically Relevant Tool for Detecting Active Non-sarcoidotic Myocarditis?Nuclear medicine and molecular imaging · 2024Review
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
purposeTo evaluate the in-treatment diagnostic accuracy of FDG PET/CT in large-vessel giant cell arteritis (LV-GCA) by serial scans before and after a short course of high-dose glucocorticoid treatment.
methodsTwenty-four glucocorticoid-naïve patients with new-onset PET/CT verified LV-GCA (pre-treatment baseline PET) were prospectively included. Excluded were patients with a previous history of GCA or polymyalgia rheumatica, LV-GCA-mimicking conditions and patients on immunosuppressive therapy. All patients were treated with 60 mg of oral prednisolone daily and assigned for in-treatment FDG PET/CT after either 3 (PET3) or 10 days (PET10). Two experienced nuclear medicine physicians, blinded to patients' clinical data, reviewed the FDG PET/CT images. A visual semi-quantitative approach was used. Segmental and homogenous FDG uptake in the wall of the aorta and/or supra-aortic branches with higher uptake intensity than liver was considered consistent with vasculitis. Inter-reader reliability was evaluated.
resultsAlthough glucocorticoid treatment attenuated FDG uptake in large vessels, LV-GCA was accurately diagnosed in 10/10 patients after 3 days of treatment, but only in 5/14 patients after 10 days of treatment (p < 0.001). Interrater reliability was substantial (agreement 87%, Cohen's weighted kappa 0.70). No correlation between CRP and FDG uptake was found.
conclusionsWithin 3 days of high-dose glucocorticoid treatment, FDG PET/CT can diagnose LV-GCA with high sensitivity. This window of opportunity ensures that prompt glucocorticoid treatment can be initiated to avoid debilitating GCA complications with a limited effect on diagnostic accuracy. After 10 days of treatment, FDG PET/CT sensitivity decreases significantly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.